Federal drug tests expand to methadone—but no medical exemptions mentioned
H.R. 7967 — Heidi’s Law · Filed by Chris Smith (R-NJ) · Introduced Mar 17, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal government to add methadone testing to workplace drug tests for federal employees and transportation workers. It also mandates that the Department of Health and Human Services review and update federal drug-testing guidelines annually to include any new drugs the Secretary believes should be tested, with the Department of Transportation following suit within 60 days of each update.
Why we flagged it
The bill's core function is to expand federal drug-testing protocols to include methadone and to establish an annual review mechanism for adding newly identified substances. While framed as a safety measure, the operative mechanism is regulatory expansion of testing scope.
What the text implies
- The bill does not define 'newly identified substances' in Section 4, creating open-ended authority for HHS to add drugs to the testing panel annually without explicit congressional approval, potentially including substances with legitimate medical uses.
- No medical exemption or accommodation is mentioned for individuals on methadone maintenance therapy, a FDA-approved treatment for opioid use disorder. Testing positive could result in employment consequences even for lawful medication use.
The full analysis lists 5 implications of this text.
Who stands to gain
drug testing laboratories and service providers; workplace testing compliance vendors